Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier

Former Life Technologies CEO Greg Lucier was named chairman and interim CEO of NuVasive following the resignation of Alex Lukianov. An internal investigation by the company's board found that Lukianov did not comply with NuVasive's expense reimbursement and other policies. 

Lucier has been a board member of NuVasive since 2013. From 2003 to 2014 he was chairman and CEO of Life Techn before it was acquired by Thermo Fisher Scientific. Prior to Life Tech, he was a corporate officer at General Electric and an executive at GE Medical Systems.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.